Related Experiment Video

Updated: Jun 20, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K

Potential Target of CDK6 Signaling Pathway for Cancer Treatment

Rajesh Basnet1,2, Obed Boadi Amissah1,2, Buddha Bahadur Basnet3

  • 1CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.

Current Drug Targets
|July 23, 2024
PubMed
Abstract

Insights

Cyclin-dependent kinase 6 (CDK6) plays a dual role in cancer, driving uncontrolled cell growth while also being a therapeutic target. CDK4/6 inhibitors offer a promising strategy, but challenges remain in drug development.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Drug Discovery

Background:

  • Cancer is characterized by uncontrolled cell proliferation often linked to genetic mutations.
  • Dysregulation of Cyclin-dependent kinase 6 (CDK6), a key cell cycle regulator, contributes to tumor formation.
  • CDK6 exhibits complex roles in cancer, acting as both a driver and a potential therapeutic target.

Purpose of the Study:

  • To investigate the multifaceted role of CDK6 in cancer development and progression.
  • To explore the structural basis and functional implications of CDK6 in cellular processes.
  • To review the challenges and advancements in developing effective CDK6 inhibitors for cancer therapy.

Main Methods:

  • Literature review of existing research on CDK6 structure, function, and regulation.
  • Analysis of CDK6's involvement in cancer signaling pathways.
  • Examination of the mechanism of action and clinical status of CDK6 inhibitors.

Main Results:

  • CDK6 is crucial for cell division, and its aberrant activity promotes tumorigenesis.
  • The structure of CDK6 influences its interactions with regulatory proteins and therapeutic inhibitors.
  • CDK4/6 inhibitors represent a significant therapeutic advancement, demonstrating efficacy in certain cancers.

Conclusions:

  • CDK6 is a critical regulator of the cell cycle with a significant role in oncogenesis.
  • Targeting CDK6 presents therapeutic opportunities, but drug selectivity, potency, and cost are key considerations.
  • Ongoing research focuses on optimizing CDK6-targeted therapies and understanding their complex interactions within cancer networks.
Keywords:
CDK4/6 inhibitorsCDK6Cyclin-dependent kinasescancercancer therapydrug design and development.retinoblastoma

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.6K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

63

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K